title: T cell recognition of bcr/abl in healthy donors and in patients with chronic myeloid leukaemia.
abstract: In chronic myeloid leukaemia (CML), peptides from the fusion region of bcr3/abl2 are likely to play a role in anti-leukaemic T cell immunity. We investigated whether T cells that recognize bcr/abl fusion peptides could be detected in healthy donors and CML patients. T cell responses against bcr3/abl2 fusion peptides were analysed by gamma-interferon enzyme-linked immunospot assays after prestimulation of peripheral blood mononuclear cells in the presence of anti-CD3-antibodies and interleukin-2. Our results suggest that the T cell repertoire contains bcr3/abl2-reactive T cells in CML patients who are in cytogenetic remission, but also in some healthy individuals.
authors.affiliation: Department of Haematology and Oncology, Charité, University Medicine Berlin, Campus Virchow Clinic, Augustenburger Platz 1, 13353 Berlin, Germany. joerg.westermann@charite.de
authors.forename: Jörg
authors.initials: J
authors.lastname: Westermann
authors.forename: Claudia
authors.initials: C
authors.lastname: Schlimper
authors.forename: Günther
authors.initials: G
authors.lastname: Richter
authors.forename: Johannes
authors.initials: J
authors.lastname: Mohm
authors.forename: Bernd
authors.initials: B
authors.lastname: Dörken
authors.forename: Antonio
authors.initials: A
authors.lastname: Pezzutto
mesh_terms: D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D016044:Fusion Proteins, bcr-abl / Q000276:immunology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D016044:Fusion Proteins, bcr-abl